https://www.selleckchem.com/pr....oducts/epz004777.htm
The aim of our retrospective study is to evaluate the prognostic significance of aspirin in patients with advanced HCC treated with sorafenib. 304 patients with HCC,consecutively treated with sorafenib from May 2007 to September 2018, were included in the clinical study. Of Them 93 patients token aspirin. Progression-free survival (PFS)and overall survival (OS)were estimated with the Kaplan-Meier method and compared with the log-rank test. The concomitant use of sorafenib and aspirin was associated with a median OS of 18.3 months comp
Mi piace
Commento
Condividi
